Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis–targeting Agents in Metastatic Castration-resistant Prostate Cancer
| Autor: | Luciano G. Martelotto, Maria Docanto, Lisa Jane K. Graham, Edmond M. Kwan, Patricia Bukczynska, Sarah Q. To, Heidi Fettke, Tilman Todenhöfer, Arun Azad, Andrew Mant, Nicole Ng, Carmel Pezaro, Lisa G. Horvath, Kate L. Mahon, Phillip Parente |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Oncology medicine.medical_specialty medicine.drug_class Urology Abiraterone Acetate 030232 urology & nephrology Antineoplastic Agents 03 medical and health sciences Prostate cancer chemistry.chemical_compound 0302 clinical medicine Predictive Value of Tests Internal medicine Nitriles Phenylthiohydantoin Biomarkers Tumor medicine Humans Protein Isoforms Enzalutamide Progression-free survival Neoplasm Metastasis business.industry Abiraterone acetate Prostate-Specific Antigen medicine.disease Androgen Progression-Free Survival Androgen receptor Prostatic Neoplasms Castration-Resistant Prostate-specific antigen chemistry Receptors Androgen 030220 oncology & carcinogenesis Benzamides Biomarker (medicine) business |
| Zdroj: | European Urology. 73:818-821 |
| ISSN: | 0302-2838 |
| DOI: | 10.1016/j.eururo.2018.01.007 |
| Popis: | In 2014, a landmark study was published demonstrating that the expression of androgen receptor splice variant (AR-V) 7 was a negative predictive biomarker for response to abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. However, these results were not supported by the recently reported ARMOR3-SV phase III clinical trial, which employed an identical circulating tumour cell assay to assess AR-V7 expression. Therefore, the predictive utility of AR-V7 expression in mCRPC remains uncertain, as does any potential association between other AR-Vs and treatment response. To further investigate, we designed a highly sensitive and specific whole blood assay for detecting AR-V7 and AR-V9. We then examined for a correlation between baseline AR-V7/V9 status and treatment outcome in 37 mCRPC patients commencing abiraterone or enzalutamide. Of the patients, 24% (9/37) were AR-V–positive. Notably, prostate-specific antigen (PSA) response rates did not significantly differ between AR-V–positive (6/9) and AR-V–negative (18/28) patients (66% vs 64%, p =0.9). Likewise, median PSA progression-free survival was not significantly different between AR-V–positive and AR-V–negative patients (9.2 mo vs not reached; p =0.9). These data, which support the findings of the pivotal ARMOR3-SV clinical trial, suggest that baseline AR-V expression does not predict outcomes in mCRPC patients receiving abiraterone or enzalutamide. Patient summary Detection of androgen receptor splice variants (AR-Vs) in circulating tumour cells of advanced prostate cancer patients has been linked to resistance to abiraterone and enzalutamide. We designed a blood test to detect AR-Vs that can be performed more routinely than tests involving circulating tumour cells and found that patients with AR-Vs still benefit from these effective treatments. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect